Stockwatch: Is Mallinckrodt Deep Value Pharma?
Litigation, Depressed Sales and Bankruptcy Warning Place Stock In Value Investing Territory
The pandemic has affected generic pharmaceutical companies more than their branded brethren but accident-prone Mallinckrodt has been hit harder than most.
You may also be interested in...
For a biotech launching its first product the pandemic has compounded the usual pressures of a competitive indication against deeper-pocketed competition.
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?
Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.